This is a summary of the European public assessment report (EPAR) for Rapiscan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rapiscan.
Therapeutic Indication
### Therapeutic indication This medicinal product is for diagnostic use only. Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.
Therapeutic Area (MeSH)
ATC Code
C01EB21
ATC Item
regadenoson
Pharmacotherapeutic Group
Cardiac therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| regadenoson | N/A | 瑞加诺生 |
EMA Name
Rapiscan
Medicine Name
Rapiscan
Aliases
N/ANo risk management plan link.
